FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076828405> ?p ?o ?g. }

• W2076828405 endingPage "873" @default.
• W2076828405 startingPage "865" @default.
• W2076828405 abstract "The in vitro and in vivo antibacterial activity of A-56268 (TE-031), the 6-O-methyl derivative of erythromycin, was compared with those of erythromycin and other reference drugs. A-56268 had the same spectrum of antibacterial activity as erythromycin. A-56268 was generally 1 log2 dilution more potent or equal to erythromycin against all organisms except haemophilus influenzae and Propionibacterium acnes, for which A-56268 was 1 log2 dilution and 3 log2 dilutions, respectively, less potent. The MBC of A-56268 and erythromycin was not significantly different from the MIC against Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus epidermidis, and H. influenzae but was more than 2 log2 dilutions higher than the MICs for some Staphylococcus aureus strains. Human serum at a concentration of 50% did not change the in vitro potency of A-56268 or erythromycin. A-56268 was similar to erythromycin in being more active at pH 8.0 than at the physiologic pH of 7.3. The activity of A-56268 was synergistic with sulfamethoxazole against 4 of 12 strains of H. influenzae. In mouse protection tests, when administered orally A-56268 was more potent than erythromycin against H. influenzae, S. pyogenes, S. pneumoniae, and S. aureus. After subcutaneous administration the potencies of A-56268 and erythromycin were not statistically different from each other. A-56268 was more potent than erythromycin against Legionella infection in guinea pigs. The concentration of A-56268 in the serum and lung was higher than that of erythromycin after intraperitoneal administration. In A-56268 in the serum and lung was higher than that of erythromycin after intraperitoneal administration. In mice, the peak levels in serum of A-56268 and erythromycin were similar after subcutaneous administration and seven times higher for A-56268 after oral administration. The serum half-life of A-56268 was approximately twice that of erythromycin after administration by both routes." @default.
• W2076828405 created "2016-06-24" @default.
• W2076828405 creator A5012603743 @default.
• W2076828405 creator A5035436227 @default.
• W2076828405 creator A5048046741 @default.
• W2076828405 creator A5048225726 @default.
• W2076828405 creator A5050377850 @default.
• W2076828405 creator A5060857878 @default.
• W2076828405 creator A5069835036 @default.
• W2076828405 creator A5075699324 @default.
• W2076828405 creator A5081980199 @default.
• W2076828405 creator A5082799023 @default.
• W2076828405 date "1986-12-01" @default.
• W2076828405 modified "2023-09-27" @default.
• W2076828405 title "In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide" @default.
• W2076828405 cites W1494759533 @default.
• W2076828405 cites W1605181013 @default.
• W2076828405 cites W1967073896 @default.
• W2076828405 cites W1976510848 @default.
• W2076828405 cites W1979492511 @default.
• W2076828405 cites W1985432986 @default.
• W2076828405 cites W2018368963 @default.
• W2076828405 cites W2030371182 @default.
• W2076828405 cites W2033952626 @default.
• W2076828405 cites W2067599373 @default.
• W2076828405 cites W2076672748 @default.
• W2076828405 cites W2095207493 @default.
• W2076828405 cites W2137589262 @default.
• W2076828405 cites W2325819067 @default.
• W2076828405 cites W2414698087 @default.
• W2076828405 cites W2765027102 @default.
• W2076828405 cites W4244777265 @default.
• W2076828405 cites W2075561889 @default.
• W2076828405 doi "https://doi.org/10.1128/aac.30.6.865" @default.
• W2076828405 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/180609" @default.
• W2076828405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2949695" @default.
• W2076828405 hasPublicationYear "1986" @default.
• W2076828405 type Work @default.
• W2076828405 sameAs 2076828405 @default.
• W2076828405 citedByCount "138" @default.
• W2076828405 countsByYear W20768284052012 @default.
• W2076828405 countsByYear W20768284052013 @default.
• W2076828405 countsByYear W20768284052014 @default.
• W2076828405 countsByYear W20768284052015 @default.
• W2076828405 countsByYear W20768284052016 @default.
• W2076828405 countsByYear W20768284052017 @default.
• W2076828405 countsByYear W20768284052019 @default.
• W2076828405 crossrefType "journal-article" @default.
• W2076828405 hasAuthorship W2076828405A5012603743 @default.
• W2076828405 hasAuthorship W2076828405A5035436227 @default.
• W2076828405 hasAuthorship W2076828405A5048046741 @default.
• W2076828405 hasAuthorship W2076828405A5048225726 @default.
• W2076828405 hasAuthorship W2076828405A5050377850 @default.
• W2076828405 hasAuthorship W2076828405A5060857878 @default.
• W2076828405 hasAuthorship W2076828405A5069835036 @default.
• W2076828405 hasAuthorship W2076828405A5075699324 @default.
• W2076828405 hasAuthorship W2076828405A5081980199 @default.
• W2076828405 hasAuthorship W2076828405A5082799023 @default.
• W2076828405 hasBestOaLocation W20768284051 @default.
• W2076828405 hasConcept C142724271 @default.
• W2076828405 hasConcept C150903083 @default.
• W2076828405 hasConcept C184112429 @default.
• W2076828405 hasConcept C185592680 @default.
• W2076828405 hasConcept C204787440 @default.
• W2076828405 hasConcept C207001950 @default.
• W2076828405 hasConcept C2776925733 @default.
• W2076828405 hasConcept C2777949923 @default.
• W2076828405 hasConcept C2779306812 @default.
• W2076828405 hasConcept C2779489039 @default.
• W2076828405 hasConcept C2779900937 @default.
• W2076828405 hasConcept C2780206985 @default.
• W2076828405 hasConcept C2781253189 @default.
• W2076828405 hasConcept C3019249092 @default.
• W2076828405 hasConcept C501593827 @default.
• W2076828405 hasConcept C523546767 @default.
• W2076828405 hasConcept C54355233 @default.
• W2076828405 hasConcept C71924100 @default.
• W2076828405 hasConcept C86803240 @default.
• W2076828405 hasConcept C89423630 @default.
• W2076828405 hasConceptScore W2076828405C142724271 @default.
• W2076828405 hasConceptScore W2076828405C150903083 @default.
• W2076828405 hasConceptScore W2076828405C184112429 @default.
• W2076828405 hasConceptScore W2076828405C185592680 @default.
• W2076828405 hasConceptScore W2076828405C204787440 @default.
• W2076828405 hasConceptScore W2076828405C207001950 @default.
• W2076828405 hasConceptScore W2076828405C2776925733 @default.
• W2076828405 hasConceptScore W2076828405C2777949923 @default.
• W2076828405 hasConceptScore W2076828405C2779306812 @default.
• W2076828405 hasConceptScore W2076828405C2779489039 @default.
• W2076828405 hasConceptScore W2076828405C2779900937 @default.
• W2076828405 hasConceptScore W2076828405C2780206985 @default.
• W2076828405 hasConceptScore W2076828405C2781253189 @default.
• W2076828405 hasConceptScore W2076828405C3019249092 @default.
• W2076828405 hasConceptScore W2076828405C501593827 @default.
• W2076828405 hasConceptScore W2076828405C523546767 @default.
• W2076828405 hasConceptScore W2076828405C54355233 @default.
• W2076828405 hasConceptScore W2076828405C71924100 @default.
• W2076828405 hasConceptScore W2076828405C86803240 @default.

• next